Preconception anti-annexin A5 antibodies are associated with subsequent live birth in women with recurrent miscarriage: A retrospective study from China.

Abstract

To evaluate the correlation between the antiannexin A5 antibodies (aAnxA5) multiples of median (MOM) and subsequent pregnancy outcomes in women with recurrent miscarriage (RM). Totally, 310 RM women were included in this study and grouped into tertiles according to their MOM of preconception aAnxA5 circulating levels determined by ELISA. The effect of aAnxA5 on the pregnancy outcomes was performed using multiple logistic regression. The outcomes included early miscarriage (before 10weeks of gestation), late miscarriage (between 10 and 24weeks), ongoing pregnancy (beyond 10weeks), and live birth (after 24weeks) characterized by pregnancy with fetal heartbeat. For each unit increase in aAnxA5 MOM, the odds of live birth after 24weeks and ongoing pregnancy were reduced by 40.2% (OR= .598; 95%CI 0.406-0.882, P= .010) and 38.1% (OR= .619; 95%CI 0.424-0.904, P= .013), respectively, after adjusting for demographic and clinical characteristics. The rise in aAnxA5 MOM was associated with an increased risk of early miscarriage (OR=1.616; 95%CI 1.106-2.361, P= .013) and miscarriage (early + late miscarriage) (OR=1.671; 95%CI 1.134-2.464, P= .010). Further subgroup analyses showed a decreased risk of live birth rates after 24weeks of gestation in the two subgroups: maternal age ≥35 years (OR= .131; 95%CI 0.026-0.652), and previous pregnancy loss ≥ 3 (OR= .381; 95%CI 0.173-0.837). Higher preconception aAnxA5 MOM levels in women with RM may be linked with a decreased risk of live birth after 24weeks and an increased risk of early miscarriage, especially in individuals aged ≥35 years or with previous pregnancy losses ≥3.